PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.\', \'Beijing Institute of Radiation Medicine, Beijing, 100850, China.\', \'Beijing SH Biotechnology Co., Ltd., Beijing, 100070, China.\', \'Tianjin Fopcells Pharmaceutical Technology Co., Ltd, Tianjin, 300074, China.\', \'Beijing Institute of Radiation Medicine, Beijing, 100850, China. 139100026365@163.com.\', \'School of Stomatology, Capital Medical University, Beijing, 100006, China. slwang@ccmu.edu.cn.\', \'Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, 430064, Hubei, China. helen-1101@hotmail.com.\', \'Utooth Biological Technology Co., Ltd., Hubei Branch, Wuhan, 430060, Hubei, China. helen-1101@hotmail.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04380-5
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32532356
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all